|Bid||598.90 x 0|
|Ask||599.00 x 0|
|Day's Range||595.20 - 601.60|
|52 Week Range||461.30 - 622.00|
|PE Ratio (TTM)||253.16|
|Forward Dividend & Yield||22.50 (3.67%)|
|1y Target Est||83.97|
By Paul Sandle LONDON (Reuters) - AstraZeneca (AZN.L) is paying up to $45 million (32.25 million pounds) to increase its stake in Circassia (CIRCI.L), backing a company seeking to bounce back from the ...
The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.
A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping ...
Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis ...
Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties. ...
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines WPP probes misconduct allegation against Sorrell https://on.ft.com/2GuttQE ...
Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
By Brian Marckx, CFA NASDAQ:CEMI Chembio (NASDAQ:CEMI) reported Q4 2017 financial results and provided a business update. Despite declining on a sequential basis, both product sales and total revenue ...
AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 28.2x, which is lower than the industry average of 32.9x. Although some investors may jump to the conclusion that thisRead More...